Trap for Newbies - UCM BP+ and CardieX CDX NOT similar

To clarify and expand on: niloony - 19/04/2110:00Post #: 52557023" I think the market looks at ASX.CDX and has low expectations of the BP+ but we're positioned better so could be a major catalyst." ...
It is easy to miss the wisdom in this statement : The Trap for Newbies is that at a casual glance - UCM BP+ and CardieX (ASX CDX} may seem to be similar products - THIS IS NOT THE CASE!
Even this morning the price of CDX shares rose following the UCM announcement - with some aiming to benefit from the cheaper share price of CDX - until the market realized the difference!

The BP+ is in a superior, well tested and proven class of its own, covered by USCOM patents.
It started life as the Pulsecor R6.5, was purchased by USCOM well over a decade ago and has since been tweaked, developed, stress tested on the International Space Station and empowered with Tele Health software. To find out more about the BP+ machine please follow this link to https://www.uscom.com.au/
The BP+ has a very wide market - from Sports Medicine to routine Heart Performance Testing as a Service.
The following is just one example - an extract from a New Zealand health screening service who are offering a regular Heart Performance check.
"Uscom BP+is a supra-systolic oscillomeric central blood pressure (cBP) device which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm (information only previously available using invasive cardiac cathetarisation). While traditional blood pressure tests monitor the brachial blood pressure, the BP+ is able to monitor the central systolic pressure – which is the central blood pressure that affects the internal organs. This is a much more accurate identifier of heart health and is one of the most important measurements we will be taking in your appointment."
https://www.healthscreeningnz.com/pulse-wave-analysis

Accuracy of the Sphygmocor Xcel cuff device (AtCor Medical, CardieX, Sydney, Australia)
Published last year were the results of a trial involving 296 patients (mean age 61±12 years) using the Cardiex device. This recent validation study (2020;76:244–250) was structured to test the claims being made for this device and the accuracy of this device for measuring central BP.
CONCLUSION: Irrespective of cuff calibration technique, the Sphygmocor Xcel cuff device does not meet the Artery Society accuracy criteria for noninvasive measurement of central BP.

Measurement Using the Sphygmocor Xcel Cuff Device.
Martin G. Schultz, Dean S. Picone, Matthew K. Armstrong, J. Andrew Black, Nathan Dwyer, Philip Roberts-Thomson, James E. Sharman.Originally published1 Jun 2020 Hypertension. 2020;76:244–250
Full details at : https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.14916

Good luck to all!